Approved breast cancer drug under Real-World watch in korea
NCT ID NCT06927648
Summary
This study monitors the safety and effectiveness of the already-approved breast cancer drug Capivasertib as it is used in everyday medical practice in South Korea. It aims to track any side effects and see how well the drug works for about 130 patients who are prescribed it according to the approved label. The goal is to gather real-world information after the drug's initial approval to ensure it performs as expected in regular clinical settings.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
NOT_YET_RECRUITINGBusan, 49267, South Korea
-
Research Site
NOT_YET_RECRUITINGDaejeon, 34943, South Korea
-
Research Site
RECRUITINGDaejeon, 35015, South Korea
-
Research Site
RECRUITINGGoyang-si, 10380, South Korea
-
Research Site
RECRUITINGGuri-si, 11923, South Korea
-
Research Site
NOT_YET_RECRUITINGIncheon, 22332, South Korea
-
Research Site
RECRUITINGSeoul, 6591, South Korea
-
Research Site
RECRUITINGUijeongbu-si, 11765, South Korea
Conditions
Explore the condition pages connected to this study.